Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG daily Stock Chart
Novartis AG
Index- P/E28.82 EPS (ttm)2.77 Insider Own9.30% Shs Outstand2.59B Perf Week5.42%
Market Cap206.84B Forward P/E15.25 EPS next Y5.24 Insider Trans0.40% Shs Float2.58B Perf Month3.91%
Income6.72B PEG7.33 EPS next Q1.18 Inst Own10.30% Short Float0.20% Perf Quarter10.09%
Sales50.00B P/S4.14 EPS this Y-33.30% Inst Trans1.73% Short Ratio2.28 Perf Half Y-4.20%
Book/sh30.19 P/B2.65 EPS next Y11.56% ROA5.10% Target Price91.88 Perf Year-19.82%
Cash/sh- P/C- EPS next 5Y3.93% ROE8.90% 52W Range68.87 - 102.83 Perf YTD-3.52%
Dividend2.72 P/FCF146.18 EPS past 5Y-7.50% ROI7.80% 52W High-22.30% Beta0.60
Dividend %3.40% Quick Ratio0.60 Sales past 5Y-0.50% Gross Margin65.30% 52W Low16.02% ATR1.13
Employees118000 Current Ratio0.80 Sales Q/Q-3.00% Oper. Margin17.20% RSI (14)71.15 Volatility0.93% 1.02%
OptionableYes Debt/Eq0.39 EPS Q/Q-10.90% Profit Margin13.60% Rel Volume1.00 Prev Close78.42
ShortableYes LT Debt/Eq0.23 EarningsApr 21 BMO Payout93.90% Avg Volume2.26M Price79.90
Recom2.40 SMA205.62% SMA506.64% SMA200-2.02% Volume2,247,767 Change1.89%
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
May-25-16 09:41AM  Novartis' CEO Says Company Open To Selling Its $14 Billion Stake In Roche 'If The Opportunity Were Right'
05:43AM  Novartis willing to sell Roche stake without demanding premium - CEO Reuters
May-24-16 05:20PM  Novartis Filing for MabThera Biosimilar Accepted in the EU
10:25AM  The Top 5 Johnson & Johnson Shareholders (JNJ) at Investopedia
09:04AM  The Best Buys in Biopharma Today at Motley Fool
May-23-16 03:47PM  Novartis' Cardiovascular Drug Gets Positive Recommendation
12:32PM  The Impact of Novartis' New Business Model (NVS) at Investopedia
11:58AM  Novartis executive exodus complicates drugmaker's rebuilding job
May-21-16 11:06AM  Struggling Novartis heart drug boosted by new medical guidelines Reuters
May-20-16 09:35PM  [$$] Colombia Threatens to Override Novartiss Patent on Gleevec at The Wall Street Journal
06:00PM  New medical guidelines back use of Novartis heart failure drug Reuters
May-19-16 11:24AM  Will These Game-Changing Cancer Treatments Hit the Market in 2016? at Motley Fool
10:20AM  Novartis launches new Entresto trials in bid to boost sales Reuters
10:04AM  Novartis Announces The Establishment Of FortiHFy, But What Is It?
06:00AM  The Real Reason Big Pharma Wants to Help Pay for Your Prescription at Bloomberg
May-18-16 05:47PM  Colombia battles world's biggest drugmaker over cancer drug
02:57PM  Novartis (NVS) to Stop Trial on Breast Cancer Drug Early
02:06PM  Behind Amgens Plans to Penetrate the Migraine Segment
12:18PM  NT Pharma's Acquisition of Novartis's Well-known International Orthopedic Brand Miacalcic Helps to Enrich Product Portfolio and Enhance Profitability ACN Newswire
07:20AM  Colombia Is Threatening Novartis Over This Cancer Drugs High Price at Fortune
12:17AM  Novartis Pharmaceuticals Head to Depart Amid Restructuring at The Wall Street Journal
May-17-16 03:20PM  Novartis splits drugs business into two, pharma chief to leave
03:17PM  [$$] Novartis to Split Drug Division at The Wall Street Journal
11:47AM  Novartis Splits Up Drug Unit as Top Executive Will Depart at Bloomberg
May-16-16 02:54PM  Pfizer buying skin drug maker Anacor for $5.2 billion AP
11:50AM  3 things you should know about Greater Washingtons bioscience companies at American City Business Journals
09:43AM  Novartis (NVS) Releases Positive Data on Ultibro Breezhaler Zacks
May-13-16 10:15AM  Parsing the Rapidly Changing Landscape of the $300 Billion Pharmaceutical Sector at TheStreet
May-11-16 01:05AM  Analyzing the Changes in Novartiss Valuation for 1Q16 Market Realist
May-09-16 04:07PM  Pfizers 1Q16 Earnings: Products That Saw Sales Drop Market Realist
03:55PM  Momenta Pharmaceuticals: Waiting for Fewer Injections at Motley Fool
May-08-16 08:15PM  3 Catalysts That Will Drive AERI Higher in 2015 (AERI, VRX) at Investopedia
May-06-16 10:39AM  This CEO of a small Boston biotech earned more than the CEOs of Novartis, Roche at American City Business Journals
May-04-16 04:05PM  Alcon Continued the Declining Trend in Its 1Q16 Earnings Market Realist
May-03-16 08:30PM  As Google's secretive biotech spinoff ramps up, look who it's hiring at American City Business Journals
08:24AM  [$$] Shannon Klinger to Replace Eric Cornut as Novartis's Ethics Officer at The Wall Street Journal
07:26AM  Move over, wearables. Swallowable computing has arrived at CNBC
May-02-16 04:51PM  Radius Health (RDUS): Stock to Surprise in Q1 Earnings? Zacks
11:21AM  The Single Most Important Thing About GlaxoSmithKline's Q1 Report at Motley Fool
11:06AM  2 Dirt-Cheap Big Pharma Stocks Poised to Beat Biotech's Bad Rap at TheStreet
Apr-28-16 01:36PM  ETFs with exposure to Novartis AG : April 28, 2016 at Capital Cube
10:06AM  Tysabri Reports Strong Patient Growth in 1Q16 Market Realist
Apr-27-16 11:06AM  Analysts Recommendations: Most Rate Novartis a Buy Market Realist
10:13AM  [$$] Sir Andrew Witty fuels GSK turnround hopes with results boost at Financial Times
10:05AM  Novartis AG :NVS-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
07:05AM  Glaxo Profit Rises for First Time Since 2013, Tops Estimates at Bloomberg
05:05AM  Novartiss Pharmaceutical Revenue Reported Growth in 1Q16 Market Realist
Apr-26-16 07:09PM  Why Did Sandoz Report Operational Growth? Market Realist
Apr-25-16 11:34AM  Novartiss 1Q16 Earnings Got a Neutral Response from Investors Market Realist
11:34AM  Novartis Reported Operational Growth in Its 1Q16 Earnings Market Realist
09:02AM  Novartis may dispose $13.8B in Roche stake CNBC
05:50AM  April 25 Premarket Briefing: 10 Things You Should Know at TheStreet
12:06AM  [$$] Big Pharma Gets Solace From Europe at The Wall Street Journal
Apr-24-16 09:55AM  Novartis to prepare the sale of its Roche stake: Sonntagszeitung Reuters
Apr-22-16 06:49PM  Does Biotechs Recent Bounce Have Legs? Gurufocus
06:00PM  Biogen Inc Earnings Explode Higher, Revenue Not So Much at Motley Fool
10:20AM  Novartis (NVS) Q1 Earnings Miss; Gleevec Hit by Generics Zacks
08:52AM  Is U.S. Drug Pricing Debate Leaving Europe Feeling Good? at The Wall Street Journal
12:30AM  [$$] Novartis Earnings Fall on Slide in Cancer-Drug Sales at The Wall Street Journal
Apr-21-16 10:41AM  Novartis CEO says "legacy" bribery allegations provisioned for Reuters
10:10AM  Cambridge puts an A (for art) into STEM education, generates some STEAM at American City Business Journals
09:23AM  Europe Warms to New Novartis Heart Drug Amid Glacial U.S. Sales at Bloomberg
09:20AM  [$$] Novartis chief warns of paradigm shift to slower US drug sales at Financial Times
08:25AM  4 Top Jefferies Dividend-Paying Value Stocks to Buy Now at 24/7 Wall St.
08:20AM  Fighting Cancer With Killer T-Cells: 5 Developments To Watch at Forbes
07:59AM  [$$] Novartis Earnings Fall on Slide in Cancer-Drug Sales at The Wall Street Journal
05:33AM  Novartis profits hurt from generic drug competition CNBC
04:42AM  Novartis profits dip as generic rival challenges cancer drug AP
04:36AM  New heart drugs struggle to win sales as doctors hold back Reuters
02:41AM  Novartis (NVS) Misses On Earnings & Sales in Q1 Zacks
01:08AM  Novartis Profit Falls as Blockbuster Cancer Drug Sales Drop at Bloomberg
Apr-19-16 10:00AM  How Will Drug Stocks BIIB, ABT, NVS Perform in Q1 Earnings?
05:50AM  Roche sales set hard challenge for drug industry rivals
Apr-18-16 11:47AM  Will Weak Alcon Sales Hurt Novartis' (NVS) Q1 Earnings?
09:36AM  [$$] Clouds gather over Novartis as it battles series of setbacks at Financial Times
Apr-13-16 09:07AM  IBB Large-Caps: Mylan Launches Generic Version of Lopressor
Apr-12-16 09:38AM  Novartis AG downgraded by Morgan Stanley
Apr-11-16 03:30PM  Novartis Binocrit's Subcutaneous Formula Gets EC Approval
01:59PM  $35M deal: Incyte licenses Lilly drug for potential new use at
01:06PM  Why Kite Pharma, Inc. Stock Dwindled 10% in March at Motley Fool
Apr-10-16 07:40AM  Could This Biotech Company Be About to Soar Higher? at Motley Fool
02:24AM  VTIAX: Vanguard International Stock Fund's Top 5 Holdings Analysis at Investopedia
Apr-09-16 12:06AM  What Are Incytes Revenue Streams?
Apr-07-16 10:40AM  Novartis' Revolade Approved for Pediatric Patients in the EU
10:30AM  Incyte Buys Rights to Jakafi for Graft-Versus-Host Disease
Apr-06-16 06:16PM  This Deal Sent Incyte Shares Soaring 12% Today at Motley Fool
04:04PM  What Are Novartiss Valuation Multiples?
10:50AM  Pfizer's (PFE) Biosimilar of Remicade Receives FDA Approval
Apr-05-16 07:28AM  Pfizer Vs. Obama: The Treasury Tries To Stop Pharma's Tax Dodge at Forbes
Apr-04-16 05:37PM  Novartis (NVS) Releases Positive Data on Cardiovascular Drug
04:14PM  Fed Worries, Crude Oil Team Up to Beat Down Wall Street at TheStreet
07:05AM  What Do Analysts Expect for Pfizers Profitability?
Apr-03-16 06:55PM  [$$] GSK returns to battle against cancer at Financial Times
Apr-02-16 09:00AM  Novartis takes Entresto case to U.S. cardiologist meeting
Apr-01-16 07:00AM  These Stocks Still Have Room to Run at Morningstar
Mar-31-16 06:06PM  Will Novartiss Alcon Revenues Fall Further in 1Q16?
05:26PM  Opdivo: Bristol-Myers Squibbs Blockbuster Drug
02:35PM  Big Pharma companies that have paid the most in fines at
02:09PM  Pfizer Tops List of Best Biopharmaceutical Brands at TheStreet
08:48AM  Portola's APEX Trial Design Was Too Clever By Half at Forbes
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Institutes for BioMed10% OwnerMay 11Buy18.00277,7774,999,9865,573,658May 11 06:57 PM
Novartis Bioventures Ltd10% OwnerApr 12Buy10.00300,0003,000,0002,310,924Apr 12 05:09 PM
Novartis Bioventures Ltd10% OwnerFeb 17Buy8.00375,0003,000,0001,873,791Feb 17 06:47 PM